Skip to main content
. 2019 Mar 15;10:331. doi: 10.3389/fimmu.2019.00331

Figure 2.

Figure 2

Immunogenicity of PSNPs-MSP4/5 is comparable to CFA/IFA adjuvanted vaccines. BALB/c mice were immunized intradermally (100 μl per immunization) with one (PSNPs-MSP4/5 x1) or two (PSNPs-MSP4/5 x2) immunizations of PSNPs-MSP4/5 (100 μg/ml), or MSP4/5 in CFA (100 μg/ml MSP4/5 mixed 1:1 v/v in CFA) followed by MSP4/5 in IFA (100 μg/ml MSP4/5 mixed 1:1 v/v in IFA), or twice with PBS alone (Naïve). Ten days after the last immunization, mice were humanely sacrificed and splenocytes and serum collected for immunogenicity analysis. (A) IFNγ and (B) IL-4 producing T cells were assessed by ELISpot assay and (C) Total IgG antibody levels were measured by ELISA. Data is shown as mean SFU ± SD per group for ELISpot and mean antibody titer ± SD per group for ELISA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by two-way ANOVA for ELISPOT and one-way ANOVA for ELISA analyses. n = 6−8 mice per group.